The American Society of Gene and Cell Therapy (ASGCT) meeting is off and running in Baltimore, Maryland. Kevin Davies, PhD, editorial director and Corinna Singleman, PhD, managing editor at GEN are on the ground—in the talks, expo hall, and press room, covering as much of the news as they can. 

Here, they take a moment to chat about the start of the meeting and what they are looking forward to over the next few days. Davies discusses how this year’s conference is different from the meetings five years ago, opening workshops featuring Y. Esther Tak, PhD, Arena Bioworks, Samagya Banskota, PhD, Boston University, Jonathan Levy, PhD, Prime Medicine, Makoto Saito, PhD, Broad Institute, and Cameron Glasscock, PhD, University of Washington. They both share their thoughts on an interview with Mammoth’s CSO Lucas Harrington, and the news about the DAYLIGHT trial. Singleman shares her first impressions of ASGCT as a first-time attendee, some interesting talks during the “Prospects for Prenatal Gene and Cell Therapy” session Tuesday morning, and how things are going in the exhibition hall. 

Previous articleCapsida Biotherapeutics Presents Preclinical Data for Parkinson’s Disease
Next articleDevelopment of Stomach’s Acid-Secreting Cells Requires ERR-gamma